Arterra Bioscience Spa · MIL:ARBS
Arterra Bioscience Spa — NEXT GEMS 2021
34 slides from Arterra Bioscience Spa's conference presentation, December 2021
Slide 1: NEXT GEMS 2021
NEXT GEMS 2021
Slide 2: Index - Topics
INDEX TO P I C S • ARTERRA AT GLANCE • POST IPO (2020-2021) MARKET CONSOLIDATION & DIVERSIFICATION • FINANCIALS
Slide 3: People Speaking Today
People Speaking Today M. GABRIELLA COLUCCI GUALTIERO IOIMO Founder, President and CEO Chief Financial Officer .
Slide 4: Arterra Bioscience - Innovative SME
Arterra Bioscience- Innovative SME Arterra Bioscience Is a biotech company listed on the “Euronext Growth Milan” market of Borsa Italiana since 2019, founded in Naples by M. Gabriella Colucci in 2004 with the aim of developing technologies and innovative solutions that find application in various in
Slide 5: A Bit of History
A Bit of History Arterra Bioscience started its activity in 2004 as a spin-off of Arena Pharmaceuticals Inc. and based its research group in an incubator laboratory in Naples WHY NAPLES? Accredited Universities and Research Centers EU Support fo Research South of Italy is part of the convergence Com
Slide 6: Biotech and its potential
Biotech and its potential BIOTECHNOLOGY BLUE GREEN WHITE RED FOR THE BIOTECH BIOTECH BIOTECH BIOTECH RESEARCH AND THE marine and agricultural raw materials gene to DEVELOPMENT OF fresh water processes and to valuable drug NEW ACTIVE organisms plants products discovery COMPOUNDS TESTING DISCOVERY PLA
Slide 7: Our Business Model
Our Buisiness Model Research Grants Research Contracts Scientific Breakthrough New Technology Market needs RESEARCH IDEA INTERNAL SCIENTIFIC AGRIFOOD COSMETICS COMMITTEE AGRICULTURE NUTRACEUTICAL NUTRACEUTICAL MEDICAL DEVICES Licence IP Production & EXPERIMENTATION to Third Party sales INTERNAL COMM
Slide 8: Our Business Model: Vitalab
Our Business Model: A Born in 2010 Vitalab srl, a joint venture between Arterra Bioscience and Intercos Sells ingredients Arterra Bioscience for Cosmetic End markets application through
Slide 9: Main Scientific Achievements & Prizes
Main Scientific Achievements & Prizes 16 GRANTS 22 PATENTS 3 DEPOSITED 44 SCIENTIFIC ARTICLES 60 INNOVATIVE Approved and financed Inventor/co-inventor of 17 patents: TRADEMARK Co-author of 30 scientific articles on PRODUCTS Peer Reviewed Journals for a total projects’ value of N° 7 Worldwide Patents
Slide 10: A successful IPO
A successful IPO Number of shares 6.544.580 Free Float 26,9% Market Cap ~24,2M Shares issued 2.208.000 New issue 1.536.000 Selling shares 384.000 Greenshoe 288.000 Warrants* (1: 4 shares) 552.000 Strike price (IPO Price+10%) € 2,86 1st exercise period (28 days) October 2020 IPO Shares Price €2,6 IPO
Slide 11: Diversification Phase - Use of Proceeds
Use of Proceeds • Integrate new technologies given the possibility of hiring highly qualified scientists coming from R&D different areas of biological sciences • Several R&D projects related to new products for Cosmetics, Nutraceutical, etc. CAPEX • New production equipment aimed at increasing the p
Slide 12: Post IPO 2020-2021
POST IPO 2020-2021 NEXT GEMS 2021
Slide 13: Ownership & Company Structure
Ownership & Company Structure Main Shareholders Gabriella Colucci Paolo Colucci 27.9% 7.5% Maarten Chrispeels 6.8% Industrial Shareholders Employees 14 20 28 34 8 16.5% 8.7% 2008 2013 2018 2020 2021 Other Shareholders Facilities Othher Floting Shares Shareholders 26,2% <6,4% 1600 SqM 2020
Slide 14: R&D Team
R&D Team Production and R&D team 1 11 11 7 Chem. Ing. PhD's MSc Lab technician Post IPO new expertise: Scientific Director: PhD, Prof. WUR Production Director: Chemical Engeneer Biochemist: Experinced PhD Synthetic Biology: Experinced PhD Chemistry : Experinced MSc The number does not include the ad
Slide 15: Management Team
Company Structure Post-IPO Management Team Gabriella Colucci Gualtiero Ioimo Vincenzo Fogliano Giuseppe Ferrante Marida Bimonte Annalisa Tito CEO CFO CSO COO Grant & IP Cell & Mol Biol. & Investor Relations Director Director
Slide 16: Company Organization
Company Organization President & CEO Gabriella Colucci Accounting Financial Assistenza Direzione Gualtiero Ioimo Alexandra Fellermeier Quality Control Scientific Luigi Sena Coordinator Vincenzo Fogliano Vitalab: Marketing Sales & Regulatory Grant & IP Office Production Director Director Giuseppe Fer
Slide 17: Research Units
Research Units Chemistry Plant Biology Extraction RU Lyophiliza Histology tion Molecular & Cell Biology
Slide 18: Research Units - Case study: Vita AvoCare
Research Units- Case study Intercos Vitalab Regulatory MT Stability Sourcing Extraction Chemistry Molecular Histology Clinical Test Marketing Biology Vita AvoCare 3 months research project
Slide 19: Capex
Capex Total Investment: 1.6 M New Chemistry lab New Growing capability Update Production lab Update Cell Biol Lab
Slide 20: Certifications
Certifications EE/CI
Slide 21: Production Capabilities
Production Capabilities Fulfilled orders Productivity Productivity Outsourcing Year (kg) kg/day Euro/day (Euro) Cell Culture Lyophilization 2019 8860 9 3150 147.800 8.800 2020 9117 21 7350 272.636 8.000 2021 E. 14.500 21 7350 14.400 20.000 2022 50 17.500
Slide 22: M&A: To enhance the competitive advantage of Arterra
M&A To enhance the competitive advantage of ARTERRA ARTERRA ADL Research Clinical Study Development Regulatory Active Ingr. Prod. Sale network
Slide 23: Business Consolidation: New Products on the Market
Business Consolidation Innovation in COSMETICS - 2020-2021 New Products on the Market NC55 Vita Ray-Immune NC56 Anchoryl Vita NC57 Vita Adren-Align Pelargonium capitatum stem cells Scabiosa arvensis stem cells Ficus carica stem cells NC59 Vita BotaniGuard. NC60 Vita Up-Gravity NC61 Vita Avocare: Pun
Slide 24: Business Consolidation: Scientific Publications
Business Consolidation Innovation in COSMETICS - 2020-2021 Scientific Publications • Ceccacci S, et al. An Oenothera biennis Cell Cultures Extract Endowed with Skin Anti-Ageing Activity Improves Cell Mechanical Properties. Metabolites 2021, 11, 527.. • Apone F. Uses and properties of bioactive pepti
Slide 25: Business Consolidation: Patents and Grants
Business Consolidation Innovation in COSMETICS - 2020-2021 Patents • 102020000021994. Uso cosmetico di estratti derivati da colture cellulari appartenenti alla specie Oenothera biennis e composizioni cosmetiche che contengono tali estratti. • 102019000021324. Uso cosmetico di un estratto derivato da
Slide 26: Business Diversification: Medical Device
Business Diversification Innovation in MEDICAL DEVICE - 2020-2021 Scientific Publications Tito A, Et Al. Pomegranate Peel Extract as an Inhibitor of SARS-CoV-2 Spike Binding to Human ACE2 Receptor (in vitro): A Promising Source of Novel Antiviral Drugs. Front Chem. 2021 Apr 28;9:638187 A pomegranate
Slide 27: First product on the medical device market
Business Diversification First product on the medical device market
Slide 28: Business Diversification: Medical Device & Nutraceutical
Business Diversification MEDICAL DEVICE & NUTRACEUTICAL Grant NUTRABEST - Fondo Crescita Sostenibile “Agrifood”, DM 5.3.2018, (Gennaio 2020 -Gennaio 2023) - Sviluppo di piattaforme molecolari e cellulari per l’identificazione di prodotti innovativi ad attività NUTRAceutica da Biotrasformazioni media
Slide 29: Business Diversification: Agrifood
Business Diversification AGRIFOOD June 2021 Arterra Bioscience and Montecarlofruit S.a.r.l., specialized in the production of aseptic mango fruit purea for baby food, in Mali, signed a research agrement for the up-cycling of the mango waste.
Slide 30: Financials
FINANCIALS NEXT GEMS 2021
Slide 31: Limited production costs driving profitability
Limited production costs driving compelling profitability: thriving upside arising from additional revenues to be mostly converted in EBITDA Turnover (€/000) Ebitda (€/000) Net Income (€/000) 3.626 2.978 136 37,2% 2.745 37,7% 34,1% 35,1% 119 1.351 34,4% 25,7% 799 23,6 556 % 1.602 2.822 1.236 2.709 1
Slide 32: First semester of 2021 results
The first semester of 2021 has shown a slight increase in revenues, while the marginality has declined due to investments in equipment and staff Turnover (€/000) EBIT & EBITDA (€/000) Net Income (€/000) 2.074 = % margin on VdP = % margin on VdP 1.873 2.066 510 374 492 39,6% 37,0% 29,7% 20,9% 31,0% 1
Slide 33: Key Highlights
Key Highlights Bioscience great momentum since environmental 1 sustainability is becoming crucial for a huge number of industries Biotech company with an outstanding 2 R&D and highly qualified Technology Team A global reach and presence with low 3 commercial investments Huge potential in the referen
Slide 34: Thanks
THANKS NEXT GEMS 2021